Home

Schizophrenia

Bipolar, Schizophrenia

Read time: 3 min

Congress highlights

Reconceptualizing psychosis based on biomarker analysis – personalized therapy to prevent disease progression

When an extensive biomarker study characterizing diverse aspects of brain function unexpectedly...

Read time: 4 min

Congress highlights

Mutual benefits: Public–Private Partnerships in CNS Research

Public–Private Partnerships are being developed worldwide to facilitate collaboration between...

Read time: 5 min

Congress highlights

Fit for life: Environmental risk factors and schizophrenia

Risk and resilience to mental disorders have been investigated in terms of both environmental and...

John FP Bridges – Priorities of people living with SCZ

John FP Bridges - Functioning as a goal for patients living with Schizophrenia

Read time: 1 min

Control of side effects may be the key to solving the dopamine paradox of schizophrenia

Schizophrenia is a highly complex and heterogeneous disease that consists of positive symptoms,...

Depression, Schizophrenia

Read time: 4 min

Stigma – time to change attitudes

Stigma. During a symposium at this year’s EPA, four specialists advocated various approaches...

Read time: 4 min

Congress highlights

The promise of big data analysis – precision psychiatry and therapeutic targeting

Psychiatric diagnosis - according to DSM-5 - is largely based on psychiatric symptoms, with a great...

Read time: 3 min

Congress highlights

Treatment-resistant schizophrenia and the impact on caregivers: A focus group study

Treatment-resistant schizophrenia (TRS), clinically defined as failure to respond to two trials of...

Read time: 5 min

Congress highlights

Updating DSM-5 to improve diagnostic validity and reliability and clinical utility

Clinicians and researchers are invited to submit proposals for revisions to the fifth edition of...

Read time: 2 min

Antipsychotic treatment response worsens in relapses following response in first episode schizophrenia

Treatment-resistant schizophrenia (TRS) is increasingly being recognized as a focus area in...

Read time: 6 min

SMART works in psychosis

Smart applications that use mobile devices and computers to track symptoms and facilitate treatment...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country